MIR4274: A Potential Drug Target and Biomarker (G100422826)
MIR4274: A Potential Drug Target and Biomarker
MIR4274, a gene encoding a protein known as mir4274, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique structure and function have made it an attractive target for researchers to study and develop new treatments.
The MIR4274 gene was first identified in the genomic database using a technique called transcriptome sequencing. This technology allows researchers to identify and measure the expression of genes in a organism, providing insights into the functions of the genes. The MIR4274 gene was found to be highly expressed in various tissues and organs, including brain, muscle, and pancreas, which suggests its potential involvement in these diseases.
To further investigate the function of MIR4274, researchers used a technique called RNA interference (RNAi) to knockdown the gene expression in cell culture models of cancer cells. The results showed that MIR4274 was positively correlated with the expression of the PD-L1 gene, which is a known regulator of cancer cell growth and survival. This suggests that MIR4274 may have a negative impact on cancer cell growth and may be a potential drug target.
Another study found that MIR4274 was highly expressed in the brain and that its expression was correlated with the expression of genes involved in neurodegenerative disorders. This suggests that MIR4274 may be involved in the development and progression of these disorders. Researchers are currently using RNAi to knockdown the expression of MIR4274 in animal models of neurodegenerative disorders, with the goal of studying its potential therapeutic effects.
In addition to its potential involvement in neurodegenerative disorders, MIR4274 has also been shown to be involved in autoimmune diseases. autoimmune diseases are characterized by an overreactive immune system that attacks the body's own tissues, leading to inflammation and damage. MIR4274 has been found to be highly expressed in various tissues and organs, including the gut, which is a known site of immune tolerance. This suggests that MIR4274 may be involved in the development and progression of autoimmune diseases.
Researchers are currently using RNAi to knockdown the expression of MIR4274 in animal models of autoimmune diseases, with the goal of studying its potential therapeutic effects. This work is being done in collaboration with the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which is a major funder of biomedical research in the United States.
MIR4274 has also been shown to have potential as a biomarker for several diseases. For example, it has been found to be highly correlated with the expression of the T-cell receptor alpha chain, which is a known marker for the development of cancer. This suggests that MIR4274 may be a useful biomarker for the early detection of cancer. In addition, MIR4274 has been found to be highly correlated with the expression of genes involved in cardiovascular disease, which suggests that it may also be a useful biomarker for the development of cardiovascular disease.
Research into MIR4274 is still in its early stages, but the potential for this protein as a drug target and biomarker is already clear. Further studies are needed to fully understand its functions and to develop new treatments based on its unique properties. By doing so, researchers hope to improve the health and well-being of people around the world.
Protein Name: MicroRNA 4274
The "MIR4274 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4274 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
MIR4275 | MIR4276 | MIR4277 | MIR4278 | MIR4279 | MIR4280 | MIR4281 | MIR4282 | MIR4283-1 | MIR4283-2 | MIR4284 | MIR4285 | MIR4286 | MIR4287 | MIR4288 | MIR4289 | MIR429 | MIR4290 | MIR4291 | MIR4292 | MIR4293 | MIR4294 | MIR4295 | MIR4296 | MIR4297 | MIR4298 | MIR4299 | MIR4300 | MIR4300HG | MIR4301 | MIR4302 | MIR4303 | MIR4304 | MIR4305 | MIR4306 | MIR4307 | MIR4308 | MIR4309 | MIR431 | MIR4310 | MIR4311 | MIR4312 | MIR4313 | MIR4314 | MIR4315-1 | MIR4315-2 | MIR4316 | MIR4317 | MIR4318 | MIR4319 | MIR432 | MIR4320 | MIR4321 | MIR4322 | MIR4323 | MIR4324 | MIR4325 | MIR4326 | MIR4327 | MIR4328 | MIR4329 | MIR433 | MIR4330 | MIR4418 | MIR4420 | MIR4423 | MIR4425 | MIR4427 | MIR4428 | MIR4429 | MIR4430 | MIR4431 | MIR4432 | MIR4432HG | MIR4433A | MIR4433B | MIR4435-1 | MIR4435-2 | MIR4435-2HG | MIR4436A | MIR4436B1 | MIR4436B2 | MIR4437 | MIR4440 | MIR4441 | MIR4442 | MIR4443 | MIR4444-1 | MIR4444-2 | MIR4445 | MIR4446 | MIR4447 | MIR4448 | MIR4449 | MIR4450 | MIR4451 | MIR4453 | MIR4453HG | MIR4454 | MIR4455
